Antimicrobial Agents and Chemotherapy · 2008 · 50 citations · 29 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyNonlinear PharmacokineticsPharmacokinetic ModelingCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug DispositionDrug Metabolism GeneticsPediatric PharmacologyAntimalarial Drug CombinationsCentral Volume Of DistributionCytochrome P450 Genetic PolymorphismCytochrome P450 Genotype EffectsNonlinear Drug ClearancePopulation Clearance EstimationPopulation Pharmacokinetic ClearanceTreatment Of Malaria
Artesunate (AS) is used in combination with amodiaquine (AQ) as first-line treatment for uncomplicated malaria in many countries. We investigated the effect of concomitant AS administration on the pharmacokinetics of AQ and compared concentrations of desethylamodiaquine (DEAQ), the main metabolite of AQ, in plasma between patients with different variants of the cytochrome P4502C8 (CYP2C8) gene. A two-compartment model was fitted to 169 plasma DEAQ concentrations from 103 Ghanaian children aged 1 to 14 years with uncomplicated malaria treated either with AQ alone (n = 15) or with AS plus AQ (n = 88). The population clearance of DEAQ appeared to increase nonlinearly with body weight, and the central volume of distribution of DEAQ was higher (P < 0.001) in the AS-plus-AQ group than in the AQ-only group. The maximum plasma DEAQ concentration was higher (P < 0.001), and the population distribution half-life was shorter (P < 0.01), in the AQ-only group than in the AS-plus-AQ group. The total areas under the plasma DEAQ concentration-time curves (P = 0.68) and elimination half-lives (P = 0.39) were similar for the two groups. There was a high frequency (0.179) of the non-wild-type allele of CYP2C8, but no differences between CYP2C8 genotypes with regard to AQ efficacy or safety were evident. The sample size, however, was limited, so monitoring of AQ toxicity in the study area is still indicated. The nonlinear clearance of DEAQ and the wide variability in kinetic parameters have safety implications for weight-based dosing of higher-body-weight children with AQ. The pharmacokinetics of artemisinin combination therapies should be studied in malaria patients, because the rapid parasite clearance caused by the artemisinin may affect the kinetics of the partner drug and the combination.
29
François Nosten, S. Looareesuwan, WM Watkins et al. · The Lancet · 1999 · 543 citations
Public Health, Infectious Disease Control, Infectious Diseases +11
Amodiaquine induced agranulocytosis and liver damage.
K Neftel, W Woodtly, M. Schmid et al. · BMJ · 1986 · 292 citations · Full text
Veterinary Medicine, Infectious Diseases, Pharmacotherapy +12
Xueqing Li, Anders Björkman, Tommy B. Andersson et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 285 citations